Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

Open Access Highly Accessed Research

A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time

Simon J Stanworth1*, Timothy S Walsh2, Robin J Prescott3, Robert J Lee3, Douglas M Watson4, Duncan Wyncoll5 and the Intensive Care Study of Coagulopathy (ISOC) investigators

Author Affiliations

1 Department of Haematology/Transfusion Medicine, John Radcliffe Hospital, NHS Blood & Transplant/Oxford Radcliffe Hospitals Trust, and University of Oxford, Osler Road, Headington, Oxford, OX3 9BQ, UK

2 Department of Critical Care, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh, EH16 4SB, UK

3 Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, UK

4 Scottish National Blood Transfusion Service, 25 Shelley Road, Gartnavel, Glasgow, G12 0XB, UK

5 Department of Critical Care, Guy's & St Thomas' NHS Foundation Trust, Lambeth Palace Road, St Thomas's Hospital, London, SE1 7EH, UK

For all author emails, please log on.

Critical Care 2011, 15:R108  doi:10.1186/cc10129


See related commentary by Tinmouth and McIntyre, http://ccforum.com/content/15/3/160

Published: 5 April 2011

Abstract

Introduction

Fresh frozen plasma (FFP) is widely used, but few studies have described patterns of plasma use in critical care. We carried out a multicentre study of coagulopathy in intensive care units (ICUs) and here describe overall FFP utilisation in adult critical care, the indications for transfusions, factors indicating the doses used and the effects of FFP use on coagulation.

Methods

We conducted a prospective, multicentre, observational study of all patients sequentially admitted to 29 adult UK general ICUs over 8 weeks. Daily data throughout ICU admission were collected concerning coagulation, relevant clinical outcomes (including bleeding), coagulopathy (defined as international normalised ratio (INR) >1.5, or equivalent prothrombin time (PT)), FFP and cryoprecipitate use and indications for transfusion.

Results

Of 1,923 admissions, 12.7% received FFP in the ICU during 404 FFP treatment episodes (1,212 FFP units). Overall, 0.63 FFP units/ICU admission were transfused (0.11 units/ICU day). Reasons for FFP transfusion were bleeding (48%), preprocedural prophylaxis (15%) and prophylaxis without planned procedure (36%). Overall, the median FFP dose was 10.8 ml kg-1, but doses varied widely (first to third quartile, 7.2 to 14.4 ml kg-1). Thirty-one percent of FFP treatments were to patients without PT prolongation, and 41% were to patients without recorded bleeding and only mildly deranged INR (<2.5). Higher volumes of FFP were administered when the indication was bleeding (median doses: bleeding 11.1 ml kg-1, preprocedural prophylaxis 9.8 ml kg-1, prophylaxis without procedure 8.9 ml kg-1; P = 0.009 across groups) and when the pretransfusion INR was higher (ranging from median dose 8.9 ml kg-1 at INR ≤1.5 to 15.7 ml kg-1 at INR >3; P < 0.001 across ranges). Regression analyses suggested bleeding was the strongest predictor of higher FFP dose. Pretransfusion INR was more frequently normal when the transfusion indication was bleeding. Overall, posttransfusion corrections of INR were consistently small unless the pretransfusion INR was >2.5, but administration during bleeding was associated with greater INR corrections.

Conclusions

There is wide variation in FFP use by ICU clinicians, and a high proportion of current FFP transfusions are of unproven clinical benefit. Better evidence from clinical trials could significantly alter patterns of use and modify current treatment costs.